SCHEMBL3363886

SCHEMBL3363886

O=[PH](O)Oc1ccc(Br)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LDHA P00338 1/20 0.42
MAPT P10636 2/20 0.41
LMNA P02545 2/20 0.41
MEN1 O00255 1/20 0.41
MAPK1 P28482 1/20 0.41
RAB9A P51151 1/20 0.41
KMT2A Q03164 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41
CA2 P00918 4/20 0.40
CA1 P00915 3/20 0.40
CA9 Q16790 2/20 0.40
CYP2A6 P11509 1/20 0.38
CES2 O00748 1/20 0.37
CES1 P23141 1/20 0.37
ALOX15 P16050 1/20 0.36
RXRA P19793 1/20 0.35
RXRB P28702 1/20 0.35
POLB P06746 1/20 0.34
MMP2 P08253 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15849787 0.87 MEN1 (0.30) MEN1KMT2A
SCHEMBL31285725 0.81 NCEH1 (0.49) MAPTLMNAMEN1MAPK1RAB9A
SCHEMBL3363883 0.80 CA1 (0.43) LDHAMAPTLMNAMEN1MAPK1
SCHEMBL4104276 0.78 MEN1 (0.48) MAPTLMNAMEN1RAB9AKMT2A
SCHEMBL8476586 0.76 MAPT (0.41) LDHAMAPTLMNAMEN1MAPK1
SCHEMBL4074417 0.76 TDP1 (0.46) MAPTMEN1MAPK1RAB9AKMT2A
SCHEMBL17061022 0.76 CA1 (0.52) MAPK1RAB9ACA2CA1CA9
SCHEMBL7867649 0.76 ALDH1A1 (0.39) KMT2ACA2CA1CA9CES2
SCHEMBL18037119 0.76 HPGD (0.41) MAPTLMNAMEN1KMT2ACA2
SCHEMBL29061609 0.76 CA1 (0.40) CA2CA1CA9RXRARXRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118679172-A Process for producing phenylphosphonate and phenylphosphonate compound 日产化学株式会社 2024-09-20 CN disclosed
WO-2024083210-A1 COMPOUNDS, COMPOSITIONS AND METHODS THEREOF HEPAITECH (BEIJING) BIOPHARMA TECHNOLOGY CO., LTD. (CN) 2024-04-25 WO disclosed
CN-116462709-A Phosphate group-containing compound, preparation method thereof and application thereof in perovskite light-emitting device 中国科学院长春应用化学研究所 2023-07-21 CN disclosed
WO-2023016546-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. (US) 2023-02-16 WO disclosed
CN-115698003-A Heterocyclic GLP-1 agonists 加舒布鲁姆生物公司 2023-02-03 CN disclosed
EP-4097099-A1 HETEROCYCLIC GLP-1 AGONISTS Gasherbrum Bio, Inc. (US) 2022-12-07 EP disclosed
WO-2021155841-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. (US) 2021-08-12 WO disclosed
US-9920083-B2 Image recording paper medium and image recording method FUJIFILM CORPORATION (JP) 2018-03-20 US disclosed
US-20160250866-A1 IMAGE RECORDING PAPER MEDIUM AND IMAGE RECORDING METHOD FUJIFILM CORPORATION (JP) 2016-09-01 US disclosed
US-7649015-B2 Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds GILEAD SCIENCES, INC. (US) 2010-01-19 US disclosed
US-20060199788-A1 Anti-inflammatory phosphonate compounds GILEAD SCIENCES, INC. 2006-09-07 US disclosed
EP-1663254-A2 ANTI-INFLAMATORY PHOSPHONATE CONJUGATES GILEAD SCIENCES, INC. (US) 2006-06-07 EP disclosed
US-20050239054-A1 Method and compositions for identifying anti-HIV therapeutic compounds GILEAD SCIENCES. INC. 2005-10-27 US disclosed
US-20050209197-A1 Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds GILEAD SCIENCES, INC. 2005-09-22 US disclosed
WO-2005064008-A1 METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. (US) 2005-07-14 WO disclosed
EP-1509537-A2 CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH GILEAD SCIENCES, INC. (US) 2005-03-02 EP disclosed
WO-2004100960-A2 ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS GILEAD SCIENCES, INC. (US) 2004-11-25 WO disclosed
WO-2003090690-A2 CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH GILEAD SCIENCES, INC. (US) 2003-11-06 WO disclosed
US-3970620-A Polyvinylchloride compositions for frothing DIAMOND SHAMROCK CORPORATION (US) 1976-07-20 US disclosed
US-3945955-A OPEN-CELLED FOAMS BY MECHANICAL WHIPPING DIAMOND SHAMROCK CORPORATION (US) 1976-03-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050209197-A1 Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds PPA1, PPME1, PNP LDHA 1734/4885MAPT 1039/4885LMNA 2684/4885
US-20050239054-A1 Method and compositions for identifying anti-HIV therapeutic compounds CES1, PNP, PGLS LDHA 1703/4885MAPT 3202/4885LMNA 3295/4885
US-20060199788-A1 Anti-inflammatory phosphonate compounds PHOSPHO1, TNF, PTGES LDHA 743/4885MAPT 2574/4885LMNA 2591/4885
US-20160250866-A1 IMAGE RECORDING PAPER MEDIUM AND IMAGE RECORDING METHOD PHOSPHO1, ITPR2, PPIP5K2 LDHA 4543/4885MAPT 2990/4885LMNA 3055/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.